Health
UK Researchers Prepare NHS Trial for Nitrous Oxide as Rapid Depression Treatment
Researchers at the University of Birmingham are preparing the first National Health Service (NHS) trial to test whether nitrous oxide, commonly known as “laughing gas,” can be safely and effectively used to treat severe or treatment-resistant depression. The move follows a major analysis combining the strongest clinical evidence to date on the gas’s potential antidepressant effects.
The study, published in eBioMedicine, examined how medically administered nitrous oxide (N₂O) affects adults with major depressive disorder (MDD) and treatment-resistant depression (TRD). TRD is typically diagnosed when patients fail to respond to at least two standard antidepressants, a situation affecting almost half of UK patients, earlier research indicates.
The analysis found that a single session inhaling 50 percent nitrous oxide produced significant reductions in depressive symptoms within 24 hours. These effects, however, were often short-lived, generally fading within a week. Repeated sessions appeared to provide more lasting improvements, echoing findings from studies on ketamine, another fast-acting treatment thought to influence similar glutamate pathways in the brain.
“Depression is a debilitating illness, made even more challenging by the fact that standard antidepressants do not provide meaningful relief for nearly half of patients,” said Kiranpreet Gill, PhD researcher at the University of Birmingham and lead author of the report. “This study consolidates the best available evidence suggesting that nitrous oxide can offer rapid and clinically significant short-term relief for patients with severe depression.”
While side effects such as nausea, dizziness, and headaches were relatively common, they were generally brief and no immediate safety concerns were identified. Researchers caution that the long-term effects of repeated nitrous oxide use remain largely unknown, and the limited number of trials makes it difficult to draw firm conclusions at this stage.
The work is part of the NIHR-funded Mental Health Mission Midlands Translational Centre, which aims to improve care for patients with severe and treatment-resistant depression. The upcoming NHS trial will assess whether nitrous oxide can be delivered safely and acceptably in clinical settings, potentially adding a new option to the growing field of rapid-acting depression treatments.
Gill added that larger trials will be necessary to determine safe, repeatable dosing strategies and to evaluate the long-term outcomes for patients. If successful, nitrous oxide could become an important addition to current therapeutic options, offering fast relief for those who do not benefit from conventional antidepressants.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
